FDA Rejects Aldeyra's Reproxalap for Dry Eye Disease, Citing Inconsistent Trial Results
The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.